Wuxi Apptec's Target Price Raised to HK$262 by CLSA on Outperform Rating

Deep News

Sep 04

CLSA has released its latest global healthcare sector outlook, highlighting several key investment opportunities. Notably, the firm has initiated coverage on Thermo Fisher with an "Outperform" rating and a price target of $748, offering broad exposure to a biopharmaceutical investment recovery and U.S. manufacturing reshoring as a leading life sciences tools platform.

The firm has also maintained an "Outperform" rating on Switzerland's Lonza, raising its price target from 667 to 759 Swiss francs. CLSA believes its scarce biopharmaceutical manufacturing capacity will help capture growth from localization and outsourcing trends.

In the case of WUXI APPTEC, CLSA has upheld its "Outperform" rating while raising the H-share price target from HK$214.1 to HK$262. Concurrently, the A-share price target for Wuxi Apptec Co.,Ltd. (603259.SH) has been increased from RMB 187.8 to RMB 230. Despite geopolitical concerns, the firm asserts that the company's technological leadership will continue to benefit from rising demand for advanced pharmaceutical outsourcing.

Additionally, Samsung Biologics (207940.KS) has retained its "Outperform" rating with a price target of 1.8 million Korean won. The company is expected to gain from themes including peptide demand driven by the patent cliff, dual sourcing of biologics, and U.S. manufacturing reshoring.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/news/1152717067"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152717067\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152717067?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-04 12:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152717067","market":"fut","top_or_hot":-1,"title":"Wuxi Apptec's Target Price Raised to HK$262 by CLSA on Outperform Rating","media":"Deep News","content":"<p>CLSA has released its latest global healthcare sector outlook, highlighting several key investment opportunities. Notably, the firm has initiated coverage on Thermo Fisher with an \"Outperform\" rating and a price target of $748, offering broad exposure to a biopharmaceutical investment recovery and U.S. manufacturing reshoring as a leading life sciences tools platform.<br><br>The firm has also maintained an \"Outperform\" rating on Switzerland's Lonza, raising its price target from 667 to 759 Swiss francs. CLSA believes its scarce biopharmaceutical manufacturing capacity will help capture growth from localization and outsourcing trends.<br><br>In the case of <b>WUXI APPTEC</b>, CLSA has upheld its \"Outperform\" rating while raising the H-share price target from HK$214.1 to HK$262. Concurrently, the A-share price target for <b>Wuxi Apptec Co.,Ltd.</b> (603259.SH) has been increased from RMB 187.8 to RMB 230. Despite geopolitical concerns, the firm asserts that the company's technological leadership will continue to benefit from rising demand for advanced pharmaceutical outsourcing.<br><br>Additionally, Samsung Biologics (207940.KS) has retained its \"Outperform\" rating with a price target of 1.8 million Korean won. The company is expected to gain from themes including peptide demand driven by the patent cliff, dual sourcing of biologics, and U.S. manufacturing reshoring.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wuxi Apptec's Target Price Raised to HK$262 by CLSA on Outperform Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuxi Apptec's Target Price Raised to HK$262 by CLSA on Outperform Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-09-04 12:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLSA has released its latest global healthcare sector outlook, highlighting several key investment opportunities. Notably, the firm has initiated coverage on Thermo Fisher with an \"Outperform\" rating and a price target of $748, offering broad exposure to a biopharmaceutical investment recovery and U.S. manufacturing reshoring as a leading life sciences tools platform.<br><br>The firm has also maintained an \"Outperform\" rating on Switzerland's Lonza, raising its price target from 667 to 759 Swiss francs. CLSA believes its scarce biopharmaceutical manufacturing capacity will help capture growth from localization and outsourcing trends.<br><br>In the case of <b>WUXI APPTEC</b>, CLSA has upheld its \"Outperform\" rating while raising the H-share price target from HK$214.1 to HK$262. Concurrently, the A-share price target for <b>Wuxi Apptec Co.,Ltd.</b> (603259.SH) has been increased from RMB 187.8 to RMB 230. Despite geopolitical concerns, the firm asserts that the company's technological leadership will continue to benefit from rising demand for advanced pharmaceutical outsourcing.<br><br>Additionally, Samsung Biologics (207940.KS) has retained its \"Outperform\" rating with a price target of 1.8 million Korean won. The company is expected to gain from themes including peptide demand driven by the patent cliff, dual sourcing of biologics, and U.S. manufacturing reshoring.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1997245094.SGD","symbol_name":"安联神州A股基金AT Acc SGD","start_time":0,"source_url":"","article_id":"1152717067","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152717067","pubTimestamp":1788497548,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"CLSA has released its latest global healthcare sector outlook, highlighting several key investment opportunities. Notably, the firm has initiated coverage on Thermo Fisher with an \"Outperform\" rating...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603259":"药明康德","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU0611395673.USD":"NINETY ONE GSF EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU0469268626.HKD":"AB FCP I-ASIA EX JAPAN EQUITY PTF(AD","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU1046422090.SGD":"Fidelity Pacific A-SGD","02359":"药明康德","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK1583":"高瓴概念","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","BK0216":"研究试验","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","EWH":"香港ETF-iShares MSCI","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","BK1141":"生命科学工具和服务","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","LU0700851271.USD":"NINETY ONE GSF EMERGING MARKETS MULTI-ASSET \"A\" (USD) ACC","BK1576":"医药外包概念","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC"},"translate_title":"里昂证券将药明康德目标价上调至262港元，评级为跑赢大盘","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":1,"EWH":1,"02359":1},"content_text":"CLSA has released its latest global healthcare sector outlook, highlighting several key investment opportunities. Notably, the firm has initiated coverage on Thermo Fisher with an \"Outperform\" rating and a price target of $748, offering broad exposure to a biopharmaceutical investment recovery and U.S. manufacturing reshoring as a leading life sciences tools platform.The firm has also maintained an \"Outperform\" rating on Switzerland's Lonza, raising its price target from 667 to 759 Swiss francs. CLSA believes its scarce biopharmaceutical manufacturing capacity will help capture growth from localization and outsourcing trends.In the case of WUXI APPTEC, CLSA has upheld its \"Outperform\" rating while raising the H-share price target from HK$214.1 to HK$262. Concurrently, the A-share price target for Wuxi Apptec Co.,Ltd. (603259.SH) has been increased from RMB 187.8 to RMB 230. Despite geopolitical concerns, the firm asserts that the company's technological leadership will continue to benefit from rising demand for advanced pharmaceutical outsourcing.Additionally, Samsung Biologics (207940.KS) has retained its \"Outperform\" rating with a price target of 1.8 million Korean won. The company is expected to gain from themes including peptide demand driven by the patent cliff, dual sourcing of biologics, and U.S. manufacturing reshoring.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}